Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2 Cho, B. C., Wang, Y., Li, Y., Wu, L., Besse, B., Marmarelis, M. E., Goto, K., Lee, J., Lee, S., Zhang, Y., Neal, J., Curtin, J., Bauml, J. M., Mahoney, J., Trani, L., Knoblauch, R. E., Tomasini, P. ELSEVIER. 2022: S1566

View details for DOI 10.1016/j.annonc.2022.10.359

View details for Web of Science ID 000897943700326